Exenatide
Brand Names: Byetta
Methodology & AI Transparency ⓘ
Exenatide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- 2 Real-world patient consensus: Real-world cohort score of 83% across 22 de-identified Exenatide entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $624.50 mail/discount cash up to $1530.03 uninsured retail (federal NADAC $276.0163).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Exenatide include nausea (10.5%), headache (9.1%), dizziness (8.4%).
Ask our AI Specialists anything about Exenatide
Exenatide Mechanism, CYP450 Pathways & DailyMed Monograph
Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.
12.1 Mechanism of Action Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. Exenatide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind and activate the human GLP-1 receptor in vitro .
Systemic exposure to Exenatide reflects Complete (~100%) parenteral systemic delivery for Exenatide (250 ug/mL Injection) absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar exenatide conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 9–16 hour t½ intervals for Exenatide half-life window (peak plasma tmax within 2.1 hours (exenatide) response profile).
Dosing protocols (250 ug/mL Injection or 5mcg/0.02ml Solution Pen-injector or 10mcg/0.04ml Solution Pen-injector) balance efficacy (83.00% patient satisfaction across 22 logs) against nausea (10.5% of reports), headache (9.1% of reports), dizziness (8.4% of reports), with strict avoidance in exenatide injection is contraindicated in patients with: a prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection.; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection ..
Prothrombin time and INR stability may fluctuate when Exenatide is added to chronic warfarin regimens.
Verify medication reconciliation lists so Exenatide is not inadvertently duplicated with another glp-1 receptor agonist.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Exenatide injection is contraindicated in patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection.
- Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection .
Logged Side-Effect Incidence (22 Reports)
Exenatide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Exenatide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glucagon-like peptide-1 receptor agonists and: What a 14,972-Participant Study Found The present meta-analysis does not suggest any increase in the risk of pancreatitis with the use of GLP-1RA. Diabetes research and clinical practice • 2014-02-15 • Meta-Analysis | N = 14,972 | 99/100 | PMID 24485345 ↗ |
| New Insights on GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature: What a 1,250,717-Participant Study Found This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. Drugs • 2026-10-15 • Meta-Analysis | N = 1,250,717 | 99/100 | PMID 42730869 ↗ |
| New Insights on Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia: What a 5,898-Participant Study Found A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898). JAMA psychiatry • 2026-09-01 • Meta-Analysis | N = 5,898 | 99/100 | PMID 42418179 ↗ |
| New Insights on Glucagon-like peptide-1 receptor agonists for weight management in mental: What a 595-Participant Study Found S-SEM(QW) may be the preferred treatment option, given its largest estimated effects versus control on body weight; however, its comparative ranking is uncertain due to sparse networks, substantial. Translational psychiatry • 2026-07-08 • Meta-Analysis | N = 595 | 97/100 | PMID 42420255 ↗ |
| New Insights on Comparative efficacy and tolerability of currently approved incretin mimetics: A: What a 660-Participant Study Found The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. Diabetes, obesity & metabolism • 2025-07-15 • Meta-Analysis | N = 660 | 97/100 | PMID 40212008 ↗ |
Exenatide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $276.0163/unit (~$8280.49/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $624.50 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1530.03 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Exenatide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Exenatide RxNorm Concept ID | 847910 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $276.0163 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1530.03 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $624.50 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 83.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Exenatide Patient Community, Cohort Filters & Dosage Logs
Deterministic Exenatide reference combining NIH RxNorm (847910), Medicaid NADAC ($276.0163/unit), and anonymous cohort outcomes (83% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Exenatide community threads and patient logs by age, biological sex, dosage, and treatment duration.
Week 17 update on Exenatide: titration timing and nausea management
FDA/PubMed Clinical Context Note: In FDA DailyMed SPL labeling (2026-05-27) and openFDA FAERS tracking for Exenatide (GLP-1 Receptor Agonist), nausea is among the most commonly logged early-titration reactions. never adjust prescription dose schedules without prescriber clearance.
Currently at week 17 on Exenatide (250 ug/mL Injection). Labs are trending in the right direction and overall tolerability is solid, though I noticed transient nausea during the first 10 days after stepping up. Curious whether taking it with dinner vs. morning meals helped others in the 60+ cohort.
Splitting meal timing and staying hydrated during weeks 1–2 made a noticeable difference for me on Exenatide. By week 4 the nausea settled completely.
Appreciate the transparent benchmark here. Having the CMS NADAC unit cost next to the $624.50 cash option gave me concrete numbers to review with my pharmacist before filling.